相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Therapeutic peptides: Historical perspectives, current development trends, and future directions
Jolene L. Lau et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action
Caslin A. Gilroy et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Integrated genomic and molecular characterization of cervical cancer
Robert D. Burk et al.
NATURE (2017)
Functional precision cancer medicine-moving beyond pure genomics
Anthony Letai
NATURE MEDICINE (2017)
A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution
Grace R. Anderson et al.
CELL REPORTS (2017)
One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer
Kelli M. Luginbuhl et al.
NATURE BIOMEDICAL ENGINEERING (2017)
Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy
Silvia von Karstedt et al.
NATURE REVIEWS CANCER (2017)
Targeting cell death signalling in cancer: minimising 'Collateral damage'
Joanna L. Fox et al.
BRITISH JOURNAL OF CANCER (2016)
Onto better TRAILs for cancer treatment
D. de Miguel et al.
CELL DEATH AND DIFFERENTIATION (2016)
Integrated genetic and pharmacologic interrogation of rare cancers
Andrew L. Hong et al.
NATURE COMMUNICATIONS (2016)
Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers
Sonja C. Lueck et al.
ONCOTARGET (2016)
Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer
Marina Devetzi et al.
SCIENTIFIC REPORTS (2016)
Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10
J. E. Allen et al.
CANCER RESEARCH (2015)
Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions
Avi Ashkenazi
JOURNAL OF CLINICAL INVESTIGATION (2015)
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
Joel D. Leverson et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation
Luke A. Gilbert et al.
CELL (2014)
Getting TRAIL back on track for cancer therapy
J. Lemke et al.
CELL DEATH AND DIFFERENTIATION (2014)
Combinatorial delivery of Crizotinib-Palbociclib-Sildenafil using TPGS-PLA micelles for improved cancer treatment
Duarte de Melo-Diogo et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2014)
ColonyArea: An ImageJ Plugin to Automatically Quantify Colony Formation in Clonogenic Assays
Camilo Guzman et al.
PLOS ONE (2014)
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
Ophir Shalem et al.
SCIENCE (2014)
Genetic Screens in Human Cells Using the CRISPR-Cas9 System
Tim Wang et al.
SCIENCE (2014)
Systematic identification of signaling pathways with potential to confer anticancer drug resistance
Colin A. Martz et al.
SCIENCE SIGNALING (2014)
XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis
M. Ehrenschwender et al.
CELL DEATH & DISEASE (2014)
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity
Zhi-Fu Tao et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy
Petra Obexer et al.
FRONTIERS IN ONCOLOGY (2014)
A Unified Model for De Novo Design of Elastin-like Polypeptides with Tunable Inverse Transition Temperatures
Jonathan R. McDaniel et al.
BIOMACROMOLECULES (2013)
A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection
M. Amiram et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2-Induced Apoptosis
Jeffery S. Swers et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Structure-guided design of a selective BCL-XL inhibitor
Guillaume Lessene et al.
NATURE CHEMICAL BIOLOGY (2013)
Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control
Miriam Amiram et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
TRAIL on trial: preclinical advances in cancer therapy
Daniel W. Stuckey et al.
TRENDS IN MOLECULAR MEDICINE (2013)
Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways
M. van Dijk et al.
CELL DEATH & DISEASE (2013)
Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement
Fubin Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets
Simone M. Schoenwaelder et al.
BLOOD (2011)
An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
Nicholas S. Wilson et al.
CANCER CELL (2011)
A public genome-scale lentiviral expression library of human ORFs
Xiaoping Yang et al.
NATURE METHODS (2011)
Recursive Directional Ligation by Plasmid Reconstruction Allows Rapid and Seamless Cloning of Oligomeric Genes
Jonathan R. McDaniel et al.
BIOMACROMOLECULES (2010)
Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer
Donal P. McLornan et al.
CLINICAL CANCER RESEARCH (2010)
Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro
Kate Connolly et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
X Chromosome-linked Inhibitor of Apoptosis Regulates Cell Death Induction by Proapoptotic Receptor Agonists
Eugene Varfolomeev et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
XIAP discriminates between type I and type II FAS-induced apoptosis
Philipp J. Jost et al.
NATURE (2009)
A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma
O. Ndozangue-Touriguine et al.
ONCOGENE (2008)
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL
Klaus W. Wagner et al.
NATURE MEDICINE (2007)
Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice
Wenge Liu et al.
JOURNAL OF CONTROLLED RELEASE (2006)
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
PL Toogood et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells
JM Cummins et al.
CANCER RESEARCH (2004)
Genetically encoded synthesis of protein-based polymers with precisely specified molecular weight and sequence by recursive directional ligation: Examples from the elastin-like polypeptide system
DE Meyer et al.
BIOMACROMOLECULES (2002)
分享论文
